# Martyn E. Caplin

Source: https://onco.cc/people/martyn-caplin/  
OnCo record `martyn-caplin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs.

## Summary

Martyn Caplin (Royal Free Hospital, London) was principal investigator of CLARINET, the trial showing lanreotide markedly prolongs progression-free survival in non-functioning gastroenteropancreatic neuroendocrine tumours, establishing somatostatin analogues as antiproliferative therapy rather than only symptom control. He leads one of Europe's largest NET centres and has chaired the European Neuroendocrine Tumor Society.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: neuroendocrine; somatostatin; uk
- Role: Professor of Gastroenterology and Neuroendocrine Tumours, Royal Free Hospital and UCL
- Specialisms: Neuroendocrine tumours; Somatostatin analogues; Gastroenterology; Guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Caplin%20ME%5BAuthor%5D%20neuroendocrine%20lanreotide

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- institutions: [Royal Free Hospital, Royal Free London NHS Foundation Trust](https://onco.cc/institutions/royal-free-hospital/)
- trials: [CLARINET](https://onco.cc/trials/clarinet/)
- journals: [Endocrine-related cancer](https://onco.cc/journals/endocrine-related-cancer/)

---
JSON: https://onco.cc/api/v1/entities/martyn-caplin.json